1,846
Views
21
CrossRef citations to date
0
Altmetric
Extra View

Overexpression of a conserved HSP40 chaperone reduces toxicity of several neurodegenerative disease proteins

, , , , , & show all
Pages 16-22 | Received 21 Nov 2017, Accepted 19 Dec 2017, Published online: 31 Jan 2018
 

ABSTRACT

TDP-43 and FUS are DNA/RNA binding proteins associated with neuronal inclusions in amyotrophic lateral sclerosis (ALS) patients. Other neurodegenerative diseases are also characterized by neuronal protein aggregates, e.g. Huntington's disease, associated with polyglutamine (polyQ) expansions in the protein huntingtin. Here we discuss our recent paper establishing similarities between aggregates of TDP-43 that have short glutamine and asparagine (Q/N)-rich modules and are soluble in detergents, with those of polyQ and PIN4C that have large Q/N-rich domains and are detergent-insoluble. We also present new, similar data for FUS. Together, we show that like overexpression of polyQ or PIN4C, overexpression of FUS or TDP-43 causes inhibition of the ubiquitin proteasome system (UPS) and toxicity, both of which are mitigated by overexpression of the Hsp40 chaperone Sis1. Also, in all cases toxicity is enhanced by the [PIN+] prion. In addition, we show that the Sis1 mammalian homolog DNAJBI reduces toxicity arising from overexpressed FUS and TDP-43 respectively in human embryonic kidney cells and primary rodent neurons. The common properties of these proteins suggest that heterologous aggregates may enhance the toxicity of a variety of disease-related aggregating proteins, and further that chaperones and the UPS may be key therapeutic targets for diseases characterized by protein inclusions.

This article refers to:

Acknowledgments

We thank E. Craig, U of Wisconsin, for anti-Sis1 antibody. This work was supported by National Institutes of Health grants 5R01GM056350 (to S.W.L.) and R01NS097542 (to S.J.B.).

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Additional information

Funding

NIH, Grant to Susan Liebman, R01GM056350 NIH, Grant to Sami Barmada, R01NS097542.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.